Clinical Trials › NCT05834855
RecruitingPhase 3
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Sponsored by Amsterdam UMC, location VUmc
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 200
Target enrollment
Apr 2023
Start date
May 2027
Expected completion
Interventions / Treatments
Rituximab
Conditions studied
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.